TIMP-1 as a tumor marker in breast cancer – An update
Authors:
Open Access
- 1 January 2008
- journal article
- review article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 47 (4) , 580-590
Abstract
Improvement of the management of breast cancer patients has high priority. In this regard, prognostic stratification needs to be improved in order to ensure proper medical treatment of all patients and furthermore predictors of response to chemotherapy are urgently needed. As new treatment opportunities emerge in the future this need will continue to grow. Thus, the search for molecular markers of prognosis and prediction is ongoing. Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) has been suggested as a marker of both prognosis and response to treatment. Several studies have demonstrated the association between TIMP-1 and prognosis in breast cancer and new studies within this area have focused on the possibility of using blood samples or paraffin embedded tissue instead of tumor tissue extracts for measurements of TIMP-1. Interestingly, recent studies have investigated the association between TIMP-1 and response to treatment showing that TIMP-1 may also carry predictive information on response to treatment. In this regard, results from studies of the molecular functions of TIMP-1 point to a role of TIMP-1 in the inhibition of tumor cell apoptosis as an explanation for the clinical findings. This review gives an update on the ongoing investigation of the potential role of TIMP-1 as a tumor marker in breast cancer. Furthermore, we link the clinical findings with studies of the molecular actions of the TIMP-1 protein, raising hypotheses that may explain why TIMP-1 could play an important role in future management of breast cancer patients.Keywords
This publication has 45 references indexed in Scilit:
- Plasma and Serum Levels of Tissue Inhibitor of Metalloproteinases-1 Are Associated with Prognosis in Node-negative Breast CancerMolecular & Cellular Proteomics, 2008
- Elevated plasma tissue inhibitor of metalloproteinase‐1 level predicts decreased response and survival in metastatic breast cancerCancer, 2007
- TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosisBritish Journal of Cancer, 2006
- Identification of CD63 as a tissue inhibitor of metalloproteinase‐1 interacting cell surface proteinThe EMBO Journal, 2006
- Novel functions of TIMPs in cell signalingCancer and Metastasis Reviews, 2006
- The association between Akt activation and resistance to hormone therapy in metastatic breast cancerEuropean Journal of Cancer, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinomaBreast Cancer Research and Treatment, 2005
- New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2002
- Do we need better prognostic factors in node-negative breast cancer?European Journal of Cancer, 2000